Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts

BACKGROUND: Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following s...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Macura, Sherrill L, Steinbacher, Jeremy L, MacPherson, Maximilian B, Lathrop, Melissa J, Sayan, Mutlay, Hillegass, Jedd M, Beuschel, Stacie L, Perkins, Timothy N, Spiess, Page C, van der Vliet, Albert, Butnor, Kelly J, Shukla, Arti, Wadsworth, Marilyn, Landry, Christopher C, Mossman, Brooke T
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3846908/
https://ncbi.nlm.nih.gov/pubmed/24024776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-400
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים